Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Genetic and physiological mechanisms of freezing tolerance in locally adapted populations of a winter annual.

Sanderson BJ, Park S, Jameel MI, Kraft JC, Thomashow MF, Schemske DW, Oakley CG.

Am J Bot. 2019 Nov 24. doi: 10.1002/ajb2.1385. [Epub ahead of print]

PMID:
31762012
2.

Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.

Perazzolo S, Shireman LM, Koehn J, McConnachie LA, Kraft JC, Shen DD, Ho RJY.

J Pharm Sci. 2018 Dec;107(12):3153-3162. doi: 10.1016/j.xphs.2018.07.032. Epub 2018 Aug 16.

3.

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.

Koehn J, Iwamoto JF, Kraft JC, McConnachie LA, Collier AC, Ho RJY.

AIDS. 2018 Nov 13;32(17):2463-2467. doi: 10.1097/QAD.0000000000001969.

4.

Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Gao Y, Kraft JC, Yu D, Ho RJY.

Eur J Pharm Biopharm. 2019 May;138:75-91. doi: 10.1016/j.ejpb.2018.04.014. Epub 2018 Apr 17. Review.

PMID:
29678735
5.

Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY.

J Pharm Sci. 2018 Jul;107(7):1787-1790. doi: 10.1016/j.xphs.2018.03.005. Epub 2018 Mar 13.

PMID:
29548975
6.

Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Sun J, Collier AC, Collins C, Shen DD, Ho RJY.

J Control Release. 2018 Apr 10;275:229-241. doi: 10.1016/j.jconrel.2018.02.003. Epub 2018 Feb 10.

7.

Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities.

Kraft JC, Treuting PM, Ho RJY.

J Drug Target. 2018 Jun - Jul;26(5-6):494-504. doi: 10.1080/1061186X.2018.1433681. Epub 2018 Feb 12.

8.

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho RJY.

J Drug Target. 2018 Jun - Jul;26(5-6):435-447. doi: 10.1080/1061186X.2017.1419363. Epub 2018 Jan 10. Review.

9.

Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention.

Krogstad EA, Ramanathan R, Nhan C, Kraft JC, Blakney AK, Cao S, Ho RJY, Woodrow KA.

Biomaterials. 2017 Nov;144:1-16. doi: 10.1016/j.biomaterials.2017.07.034. Epub 2017 Aug 1.

10.

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ.

AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405.

11.

Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ.

Nanomedicine (Lond). 2016;11(5):545-64. doi: 10.2217/nnm.16.1. Epub 2016 Feb 19. Review.

12.

Systems Approach to targeted and long-acting HIV/AIDS therapy.

Ho RJ, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J.

Drug Deliv Transl Res. 2015 Dec;5(6):531-9. doi: 10.1007/s13346-015-0254-y.

13.
14.

Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Kraft JC, Freeling JP, Wang Z, Ho RJ.

J Pharm Sci. 2014 Jan;103(1):29-52. doi: 10.1002/jps.23773. Epub 2013 Nov 25. Review.

15.

Pharmacogenetics and anaesthesia: the value of genetic profiling.

Landau R, Bollag LA, Kraft JC.

Anaesthesia. 2012 Feb;67(2):165-79. doi: 10.1111/j.1365-2044.2011.06918.x. Review.

16.

Pharmacogenetics in obstetric anesthesia.

Landau R, Kraft JC.

Curr Opin Anaesthesiol. 2010 Jun;23(3):323-9. doi: 10.1097/ACO.0b013e328339802c. Review.

PMID:
20440109
17.

An experimental paradigm for the prediction of Post-Operative Pain (PPOP).

Landau R, Kraft JC, Flint LY, Carvalho B, Richebé P, Cardoso M, Lavand'homme P, Granot M, Yarnitsky D, Cahana A.

J Vis Exp. 2010 Jan 27;(35). pii: 1671. doi: 10.3791/1671.

18.

In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.

Kraft JC, Osterhaus GL, Ortiz AN, Garris PA, Johnson MA.

Neuroscience. 2009 Jul 7;161(3):940-9. doi: 10.1016/j.neuroscience.2009.03.083. Epub 2009 Apr 9.

PMID:
19362126
21.

The retinoid X receptor ligand, 9-cis-retinoic acid, is a potential regulator of early Xenopus development.

Kraft JC, Schuh T, Juchau M, Kimelman D.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3067-71.

22.
23.

v-erbA and citral reduce the teratogenic effects of all-trans retinoic acid and retinol, respectively, in Xenopus embryogenesis.

Schuh TJ, Hall BL, Kraft JC, Privalsky ML, Kimelman D.

Development. 1993 Nov;119(3):785-98.

24.

9-cis-retinoic acid: a direct-acting dysmorphogen.

Kraft JC, Juchau MR.

Biochem Pharmacol. 1993 Aug 17;46(4):709-16.

PMID:
8363644
25.

Conceptional biotransformation of microinjected retinoids. Correlations with dysmorphogenic activities.

Kraft JC, Juchau MR.

Ann N Y Acad Sci. 1993 Mar 15;678:338-40. No abstract available.

PMID:
8494278
26.

Tissue levels of retinoids in human embryos/fetuses.

Kraft JC, Shepard T, Juchau MR.

Reprod Toxicol. 1993;7(1):11-5.

PMID:
8448410
30.

Microinjection of cultured rat embryos: studies with retinol, 13-cis- and all-trans-retinoic acid.

Lee QP, Juchau MR, Kraft JC.

Teratology. 1991 Sep;44(3):313-23.

PMID:
1948766
31.

Plasma pharmacokinetics and metabolism of 13-cis- and all-trans-retinoic acid in the cynomolgus monkey and the identification of 13-cis- and all-trans-retinoyl-beta-glucuronides. A comparison to one human case study with isotretinoin.

Kraft JC, Slikker W Jr, Bailey JR, Roberts LG, Fischer B, Wittfoht W, Nau H.

Drug Metab Dispos. 1991 Mar-Apr;19(2):317-24. Erratum in: Drug Metab Dispos Biol Fate Chem 1991 Jul-Aug;19(4):846.

PMID:
1676630
32.

Embryonic retinoid concentrations after maternal intake of isotretinoin.

Kraft JC, Nau H, Lammer E, Olney A.

N Engl J Med. 1989 Jul 27;321(4):262. No abstract available.

PMID:
2747765
33.

The holly oak shell.

Custer JF, Kraft JC, Wehmiller JF.

Science. 1989 Jan 13;243(4888):151-2. No abstract available.

PMID:
2911725
34.

Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice.

Reiners J, Löfberg B, Kraft JC, Kochhar DM, Nau H.

Reprod Toxicol. 1988;2(1):19-29.

PMID:
2980988
35.
36.

In reply: the holly oak pendant.

Kraft JC, Custer JF.

Science. 1985 Jan 18;227(4684):244-6. No abstract available.

PMID:
17742083
37.

Geomorphic reconstructions in the environs of ancient troy.

Kraft JC, Kayan I, Erol O.

Science. 1980 Aug 15;209(4458):776-82.

PMID:
17753292
38.

Paleogeographic reconstructions of coastal aegean archaeological sites.

Kraft JC, Aschenbrenner SE, Rapp G Jr.

Science. 1977 Mar 11;195(4282):941-7.

PMID:
17735653
39.

Early man at holly oak, delaware.

Kraft JC, Thomas RA.

Science. 1976 May 21;192(4241):756-61. No abstract available.

PMID:
17777164
40.

Vesicular vaginitis.

EHMER EA, KRAFT JC, CUMMINGS FC.

North Am Vet. 1950 Jul;31(7):463. No abstract available.

PMID:
15423748

Supplemental Content

Loading ...
Support Center